Bringing back the woolly mammoth and other extinct creatures may be impossible
By Elizabeth Pennisi,
Science
| 03. 09. 2022
An extinct rat that once lived on an island in the Indian Ocean may have put the kibosh on scientists’ dreams of resurrecting more famous extinct animals like the woolly mammoth. The Christmas Island rat disappeared just over 100 years ago, but researchers now say even its detailed genome isn’t complete enough to bring it back to life.
The work “shows both how wonderfully close—and yet—how devastatingly far” scientists are from being able to bring back extinct species by genetically transforming a close relative in what’s called “de-extinction,” says Douglas McCauley, an ecologist at the University of California, Santa Barbara, who was not involved with the study.
No species has yet been revived, but de-extinction appeals to many geneticists and futurists. “I know a lot of biologists who think, ‘Can I do this?’” says Karen Wendling, an ethicist at the University of Guelph. Part of the fascination is simply the promise of seeing a vanished species come to life. But putting a key animal back into its original... see more
Related Articles
By Sarah Zhang, The Atlantic | 06.22.2022
Photo by ANIRUDH on Unsplash
In October 2019, Jordan Janz became the first person in the world to receive an experimental therapy for cystinosis, a rare genetic disease. The treatment was physically grueling. Doctors extracted blood stem cells from Janz’s...
By Ian Sample , The Guardian | 06.22.2022
More than half the UK backs the idea of rewriting the DNA of human embryos to prevent severe or life-threatening diseases, according to a survey.
Commissioned by the Progress Educational Trust (PET), a fertility and genomics charity, the Ipsos poll...
By Fiorella Valdesolo, WSJ Magazine | 06.08.2022
“Where is the we?” It’s the question that was the driving force for Vida Delrahim and Ronit Menashe when they created WeNatal, a new brand of prenatal supplements that aims to be more inclusive. In the process of trying...
By Michael Le Page, New Scientist | 06.16.2022
CRISPR gene-editing trials for treating sickle cell disease and beta thalassaemia are being extended to include children aged under 12 after the therapies proved successful in ongoing trials involving people aged between 12 and 35. The aim is to treat...